What We're Reading: Page 77
Industry reads hand-picked by our editors
Sep 07, 2023
-
The Atlantic
We Have No Drugs to Treat the Deadliest Eating Disorder
-
FirstWord Pharma
J&J scraps late-stage pulmonary hypertension study of macitentan
-
Gizmodo
Counterfeit Pills Are Becoming Deadlier in America
-
The Wall Street Journal
Health-Insurance Costs Are Taking Biggest Jumps in Years
Sep 06, 2023
-
CNBC
Judge withdraws from Medicare drug price case after stock ownership is revealed
-
Science
As shutdown looms, will U.S. Congress cut spending and restrict research?
-
Boston Business Journal
As Needham biotech struggles with FDA, patients with an ultra-rare disease are waiting
-
The Washington Post
Rising cases in Southeast could be start of U.S. RSV season, CDC warns
Sep 05, 2023
-
The Wall Street Journal
How Novartis’s CEO Learned From His Mistakes and Got Help From an Unlikely Quarter
-
Reuters
Wegovy makes UK weight-loss debut even as Novo struggles with supplies
-
Fierce Biotech
BMS pays Zenas $50M for some rights to ex-Xencor autoimmune drug
-
The New York Times
A Huge Threat to the U.S. Budget Has Receded. And No One Is Sure Why.
Sep 01, 2023
Aug 31, 2023
-
The New York Times
Biden Makes Lower Drug Prices a Centerpiece of His 2024 Campaign
-
The Washington Post
In the Gulf, a growing scramble for Ozempic and other weight-loss drugs
-
Reuters
Blood test for Parkinson’s disease promising in early study
-
Bloomberg
Covid Isn’t Seasonal. So Why Are Covid Booster Shots?
Aug 30, 2023
-
BioCentury
Where is the sweet spot for M&A?
-
Politico
Biden’s NIH pick gives Elizabeth Warren a major concession
-
The Atlantic
How Bad Could BA.2.86 Get?
Previous
